Amid a backlash against foreign investors, some executives are banned from leaving the country
The Camry, last overhauled for the 2011 model year, just got another face-lift
Laws require companies to pay state taxes on sheltered profits
Financial filings reveal the pay package Henrique de Castro received upon exit from the company.
Wal-Mart's new money transfers shows how the retailer can use its reach to push down costs
Skipping Rocks Lab develops a green alternative to all that plastic
Alessandro Borgognone wooed Japanese chef Daisuke Nakazawa to open the four-star New York eatery
He's trying to "improve his résumé," says his lawyer
Prices are low, but there’s plenty of red tape
Founder: Dr. Mark Pruzanski
VC Investment over the last four quarters: $25 million
Founded in 2002, the 25-employee biopharmaceutical company is in the process of developing therapeutic treatment of chronic fibrotic and metabolic diseases. Despite the downturn, the company raised significant funding this year. Sticking to a tight budget, Intercept expects to have enough cash resources to fund its operations until 2010.
Key to startup success: "Be persistent. Intercept was founded just before the last major downturn for biotech, which lasted through 2003 and venture capital completely dried up for new early-stage startups. [We] remained passionately dedicated to the company and persisted even though it took more than a year to secure financing."